Phase 3 Psoriasis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with chronic plaque psoriasis for at least 6 months before the screening visit.
• Your psoriasis has been stable — meaning no major flare-ups or changes in how it looks — for at least 6 months before screening.
• Your psoriasis is considered moderate to severe, based on specific scores measured by a doctor at the screening visit and on Day 1.
• Your psoriasis covers at least 10% of your total body surface area at the screening visit and on Day 1.
• You are a suitable candidate for light therapy (phototherapy) or medication taken by mouth or injection (systemic therapy).
• For one part of the trial (Part A, Group 1): You are male or female, aged 12 up to (but not including) 18 years old.
• For another part of the trial (Part A, Group 2 and Part B): You are male or female, aged 4 up to (but not including) 12 years old.
• For Part A, Group 1 only: You weigh at least 40 kilograms (about 88 pounds) at the time of screening.

Who may not be able to join:

• You have a type of psoriasis other than plaque psoriasis, such as pustular, guttate, or drug-triggered psoriasis (a small amount of inverse psoriasis may be acceptable — confirm with trial site).
• You need regular medication (other than anti-inflammatory pain relievers like ibuprofen) to treat an immune system condition during the trial.
• You have another skin condition that, in the doctor's opinion, would affect how trial results are measured.
• You have a history of active tuberculosis (TB) at any point, currently show signs of TB, or have signs of a latent (inactive) TB infection.
• You currently have an active herpes virus infection (including cold sores or shingles), or have had a serious herpes infection in the past.
• You have a history of long-term or repeatedly occurring bacterial infections.
• You have a history of serious rare infections that typically affect people with weakened immune systems (confirm with trial site).
• You have any significant health condition, unstable health status, or abnormal test results that a doctor believes could put you at risk or affect the trial results.
• You have previously taken the study drug (zasocitinib, also known as TAK-279 or NDI-034858) or any similar type of drug, or participated in a trial involving this type of drug — unless it has been confirmed in writing that you did not receive the active drug.
• Your vaccinations are not up to date according to the recommended immunization schedule for children in your country.

Important: Always verify eligibility with the trial site directly before applying.